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Vascular endothelial growth factor (VEGF) is overexpressed in around 80% of patients with clear cell carcinoma of the kidney owing
to the inactivation of von Hippel Lindau gene activity. VEGF stimulates angiogenesis and acts as an autocrine growth factor. A number
of different agents are now available which target VEGF and its signalling pathways. A significant body of evidence has accumulated
demonstrating that antagonism of VEGF and its downstream pathways is clinically useful in a significant proportion of patients with
metastatic clear cell carcinoma of the kidney. Enough data is now available to recommend that patients with metastatic clear cell
carcinoma of the kidney should at some point during the course of their disease be offered entry into a clinical trial enabling exposure
to a targeted inhibitor of VEGF or its signalling pathways. Assuming early clinical trial data is substantiated by ongoing registration
studies, efforts should be made to minimise the time taken between licensing and general availability of these active agents.
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Systemic treatment options for renal cell carcinoma (RCC) have
been extremely limited. Standard care for metastatic disease in the
UK is with single-agent interferon-a which has a 15% response rate
and increases 1-year survival from 31 to 43% (MRC Collaborators,
1999). High-dose interleukin-2 until recently was the only drug
currently licensed by the FDA for the treatment of metastatic RCC
and at best gives durable benefit in 5–10% of patients at the
expense of significant toxicity (McDermott et al, 2005). Advances
in the understanding of the molecular biology of the most common
form of RCC, clear cell carcinoma, have shown that the von Hippel
Lindau (VHL) gene is mutated in the majority of sporadic cases
(Gnarra et al, 1994). Loss of VHL gene activity is known to
deregulate hypoxia inducible factor (HIF) which in turn leads to an
upregulation of expression of a number of genes including
vascular endothelial growth factor (VEGF), platelet-derived growth
factor, carbonic anhydrase IX, CXCR4 and tumour growth factor-a
(Siemeister et al, 1996; Semenza, 2003). VEGF is known to be
overexpressed in RCC (Nicol et al, 1997) and acts as a potent
stimulator of angiogenesis.
VASCULAR ENDOTHELIAL GROWTH FACTOR
The VEGF gene family consists of six related glycoproteins: VEGF-
A, VEGF-B, VEGF-C, VEGF-D, VEGF-E and placenta growth
factor. VEGF-A is commonly referred to as VEGF and was initially
identified by its ability to increase vascular permeability. It is a
dimeric glycoprotein which exists in four major isoforms (Tischer
et al, 1991). Vascular endothelial growth factor is now known to
have multiple effects, which promote endothelial cell activation,
growth (Zachary and Gliki, 2001), longevity (Alon et al, 1995)
invasion and migration (Zachary and Gliki, 2001).
Vascular endothelial growth factor signalling is mediated by
binding to transmembrane tyrosine kinase receptors. VEGFR-1,
VEGFR-2, VEGFR-3, Neuropilin-1 (NRP-1) and NRP-2 all bind
members of the VEGF family and mediate downstream signalling.
VEGFR-2 is thought to mediate most of the pro-angiogenic effects
of VEGF (Millauer et al, 1993).
Vascular endothelial growth factor and its signalling pathways
have been extensively reviewed (Ferrara et al, 2003; Hicklin and
Ellis, 2005).
Two major anti-VEGF strategies namely, neutralising anti-VEGF
antibody and small molecule multi-targeted kinase inhibitors,
which have activity against VEGF and other signalling pathways,
have been examined in recently reported clinical trials to date
(Table 1).
Bevacizumab
Bevacizumab (Avastin) is a humanised neutralising anti-VEGF
antibody (Presta et al, 1997) which binds to all biologically active
isoforms of VEGF. The original murine antibody, A.4.6.1, had been
shown to have anti-tumour activity in pre-clinical models. In
phase I studies, bevacizumab was shown to have a half-life of
approximately 21 days (Gordon et al, 2001). Most patients
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www.bjcancer.comtolerated the antibody well although haemorrhage, thrombosis,
bowel perforation, hypertension and proteinuria have all been
reported (Gordon et al, 2001; Yang et al, 2003; Hurwitz et al, 2004).
A prospective randomised double-blind three-arm phase II
study of low (3mgkg
 1) and high (10mgkg
 1) dose bevacizumab
given 2-weekly vs placebo in metastatic RCC was the first
controlled study demonstrating clinical activity of an anti-VEGF
approach in RCC (Yang et al, 2003). A total of 116 patients with
metastatic clear cell RCC were randomised with 37–40 patients on
each arm. All patients had documented evidence of progression at
study entry and almost all had received previous cytokine therapy.
Of 116 patients, 91 were ECOG performance status 0 with the
remainder being ECOG PS 1. The three treatment arms were well
balanced in terms of MSKCC prognostic indicators (Motzer et al,
1999) (performance status, anaemia, hypercalcaemia, prior
nephrectomy). Primary objectives were time to progression
(TTP) and overall response rate. Survival was a secondary end
point as patients who progressed on the placebo arm were allowed
to crossover to low-dose bevacizumab or entry into a study of
bevacizumab in combination with thalidomide. The drug was well
tolerated with 21% of patients in the high-dose arm experiencing
grade 3 hypertension and 64% in the same treatment arm
experiencing asymptomatic proteinuria with no reduction in renal
function. Toxicities reversed upon stopping treatment. No
treatment-related deaths were seen.
The study was stopped early by the data monitoring committee
according to O’Brien-Fleming rules. A highly significant improve-
ment in TTP (HR: 2.55, Po0.001) was seen in the high-dose arm
compared to placebo. Median TTP of the high-dose arm was 4.8
months compared to 2.5 months in the placebo arm and the overall
response rate in the high-dose arm was 10%. There was a non-
statistically significant improvement in TTP of the low-dose arm
compared to placebo. No significant survival advantage was seen
although the trial was not powered for this end point.
A phase III registration study of bevacizumab vs interferon-a in
the first line treatment of metastatic RCC has recently been
performed and results are awaited.
Bevacizumab is also being evaluated in combination with other
targeted therapies. The epidermal growth factor receptor (EGFR) is
commonly expressed in RCC (Langner et al, 2004). Single-agent
gefitinib (Iressa), a targeted EGFR-tyrosine kinase inhibitor,
showed little evidence of single-agent activity in RCC (Dawson
et al, 2004). However, in pre-clinical models, downregulation of
EGFR resulted in downregulated VEGF expression (Riedel et al,
2002). The combination of bevacizumab and erlotinib (Tarceva),
another EGFR tyrosine kinase inhibitor demonstrated a 25%
response rate with a further 61% of patients having stable disease
at 8 weeks in a 63-patient phase II study (Hainsworth et al, 2005).
Median progression-free survival was 11 months and at 15 months
of follow-up, median overall survival had not been reached.
However, a recent announcement from Genetech has indicated
that in the randomised phase II trial of bevacizumab vs
bevacizumab plus erlotinib there were no advantages to the
combination (www.gene.com, press release 18 October 2005).
The efficacy of combination-targeted treatment will only be fully
described in randomised studies but early data is interesting
enough to warrant further combination studies. Currently, phase
I/II studies of bevacizumab in combination with sorafenib (see
below), CCI-779 (an mTOR inhibitor – Temsirolimus, Wyeth), and
Interleukin-2 are ongoing.
Small-molecule targeted therapies
A number of small-molecule multi-targeted kinase inhibitors are
under investigation. They inhibit signalling mediated by the type 2
VEGF receptor as well as many other signalling pathways. All of
these orally active drugs have predictable manageable toxicities
and appear well tolerated.
Sorafenib Sorafenib (BAY43-9006) is a bi-aryl urea and was
originally developed as a raf kinase inhibitor. It has IC50s in the
nanomolar range against VEGFR-2, VEGFR-3, PDGFR, flt-3, c-kit
as well as craf and braf kinases (Wilhelm et al, 2004).
Dose-limiting toxicity in phase I studies was diarrhoea and
fatigue at 800mg b.d. and skin toxicity at 600mg b.d. (Awada,
2005; Clark et al, 2005; Moore et al, 2005; Strumberg et al, 2005).
The recommended phase II dose of 400mg b.d. was examined in
a randomised discontinuation phase II study (Ratain et al, 2005).
In this novel trial design, all patients received the standard dose of
400mg b.d.. After an evaluation at 12 weeks, patients who had a
425% response continued on active drug whereas patients with
progressive disease (425% tumour growth) were taken off study.
Those with stable disease were randomised to receive either study
drug or placebo. At progression, those receiving placebo were
allowed to crossover back to active drug. This trial design has the
advantage of accurately discriminating the proportion of patients
who have disease stabilisation due to drug activity rather than to
the biology of their disease.
Of the 202 metastatic RCC patients entering the study, 144 (71%)
had tumour shrinkage or disease stabilisation at 12 weeks. Sixty-
five patients entered the randomised phase and after a further 12-
week period 16 (50%) of patients on sorafenib were progression
free compared with six (18%) of patients on the placebo arm
(P¼0.0077). The median progression-free survival (PFS) from
randomisation was 24 weeks for sorafenib compared with 6 weeks
for the placebo arm (P¼0.0087).
Preliminary data from a randomised placebo-controlled phase
III trial in the second-line treatment of 903 patients with metastatic
RCC has been reported this year (Escudier et al, 2005). All patients
had received one prior systemic treatment in the 8 months before
study entry. Only patients with clear cell carcinoma in the ‘Motzer’
good and intermediate prognosis groups were recruited. Treat-
ment and placebo arms were well balanced in terms of prognostic
factors and 57% of patients on each arm had greater than two
metastatic sites of disease. Over 80% of patients had received
cytokine-based therapy as first-line treatment and over 90% of
patients had a previous nephrectomy.
The incidence of grade 3/4 toxicity was low. Six percent of
patients experienced a grade 3-4 hand–foot syndrome and 4%
hypertension. Haematological and biochemical grade 3/4 toxicities
were rare with lymphopenia, hypophosphataemia and elevated
lipase marginally more common in the treatment arm. The most
common grade 1/2 adverse event was diarrhoea (43% sorafenib vs
13% placebo). Twelve percent of patients experienced a dose
reduction, mainly due to hand–foot syndrome or diarrhoea.
Twenty percent of sorafenib patients had a dose interruption (5%
placebo). There was no significant difference between the sorafenib
and placebo arms (10 vs 8%) in terms of discontinuation of drug.
At the planned interim analysis after 220 events, a 10% partial
response rate and 74% disease stabilisation rate was seen on the
Table 1 Activity of anti-VEGF agents in metastatic renal cell carcinoma
trials
No
ORR
(%)
CR+PR+SD
(%) PFS /TTP (months)
Sunitinib (Phase II)
Trial 1 63 40 67 8.2 (pooled analysis both
studies)
Trial 2 105 44 67
Sorafenib (Phase III) 451 10 74 5.5
AG-013736 (Phase II) 52 46 86 Not reached
Bevacizumab (Phase II) 39 10 4.8
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placebo arm. The median PFS was 5.5 vs 2.8 months (HR: 0.51).
The median overall survival of the placebo arm was 14.7 months
and at the time of analysis had not yet been reached in the
sorafenib arm (HR: 0.72, P¼0.018). All subsets (age, prognostic
group, sites of metastasis, previous cytokine treatment) appeared
to derive equal benefit (Escudier presentation, ECCO 13, Paris
2005).
Sunitinib Sunitinib (SU011248, Pfizer) is an orally active multi-
targeted receptor tyrosine kinase inhibitor with activity against
VEGFR, PDGFR, KIT, and FLT3 kinases. It showed significant pre-
clinical activity against a variety of xenograft models (Mendel et al,
2003).
Two phase II studies have examined the activity of sunitinib in
clear cell metastatic RCC in a total of 169 patients. Entry criteria
for both studies included failure of previous cytokine therapy,
adequate end-organ function and good performance status. Clear
cell histology was stipulated in the second larger study (n¼106),
whereas 87% of patients in the earlier study (n¼63) had clear cell
histology. Nephrectomy was mandatory in the second study. Data
from both studies has been combined in a meta-analysis and an
update recently reported (Hudes, G.R., ECCO, Paris 2005).
Patients were treated with sunitinib 50mg daily for a 4-week on,
2-week off 6-week cycle. The drug is well tolerated. Fatigue is the
most common grade 3 toxicity (11% of patients) with stomatitis
and hand–foot syndrome also noted. Neutropenia, increases in
serum amylase and lipase were also seen. Twenty-seven percent of
patients across both studies were dose reduced to 37.5mg, 6% of
patients were dose reduced to 25mg. FACIT fatigue scores
demonstrated fatigue during the 4-week on treatment period
which recovered during the 2-week off period. Overall however,
levels of fatigue were not significantly different from the general
non-anaemic cancer population.
Pooled analysis of the two studies (n¼168) showed a 42%
overall response rate with a further 24% of patients with stable
disease for longer than 3 months. Median PFS was 8.2 months. The
PFS for patients who had true RECIST responses was significantly
longer than patients who had stable disease as their best response
(14.8 vs 7.9 months). Median overall survival for the first study was
16.4 months and at the time of reporting had not yet been reached
for the second study.
A phase III study comparing sunitinib with interferon in the
first-line treatment of metastatic RCC has recently been performed
and results are awaited.
AG-013736 AG-013736 (Pfizer), another multi-target kinase
inhibitor with nanomolar IC50s against all three VEGF receptors
and PDGF-Rb has been examined in a phase II study of 52
metastatic RCC patients (Rini et al, 2005). Drug was given orally at
5mg b.d. Patients were of good performance status, had failed one
previous cytokine-based therapy and any hypertension had to be
well controlled as a pre-requisite for study entry. Grade 3/4 toxicity
was hypertension (15%), diarrhoea (8%) and fatigue (8%). Forty-
six percent of patients had a partial response with a further 38% of
patients having some shrinkage in the size of their disease. Only
14% of patients had no response. At 12–18 months of follow-up,
median TTP had not yet been reached.
The drug will be examined in disease that has become refractory
to other targeted kinase inhibitors.
Surrogate markers of activity
As clinical experience grows with targeted kinase inhibitors,
surrogate markers are being identified that reflect exposure to
drug. Both sorafenib and sunitinib induce an increase in
circulating VEGF levels and a decrease in soluble VEGFR levels
(Escudier et al, 2005; Norden-Zfoni et al, 2005). Changes in
monocyte levels and circulating endothelial cells have also been
noted with sunitinib (Norden-Zfoni et al, 2005). No surrogate
marker has yet been shown to conclusively correlate with anti-
tumour effect but the hope is that patients who are likely to derive
clinical benefit will ultimately be identified early using surrogate
markers of response.
CONCLUSION AND RECOMMENDATIONS
Mature phase III data from the lead compounds is awaited.
However, the available phase II and phase III data shows
significant activity in both progression-free survival and clinical
benefit (CRþPRþSD). Early indications are that there will be a
significant effect upon overall survival. Given that this is a disease
with few active treatment options for the majority of patients, there
is now a significant body of data demonstrating that this class of
agents has useful clinical activity.
We therefore believe that all metastatic clear cell RCC patients
should at some point during their treatment have the opportunity
to be exposed to a VEGF inhibitor. Patients who are of reasonable
performance status and who do not have any specific contra-
indications for anti-VEGF treatment should therefore be referred
to a centre that has access to an appropriate agent within the
context of a clinical trial. Pharmaceutical companies should be
encouraged to expand their planned extended-use programmes to
enable patients to access these active drugs pre-licensing.
Commissioners should be made aware of the fact that once
licensed, these drugs should be made available for a patient
population which up until now has had no adequate therapeutic
options.
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